T cell-specific immunosuppression using tautomycetin or PTD-conjugated protein drugs

Yonsei Medical Journal

Volumn 45, Issue 6, 2004, Pages 978-990

  Chae, Wook Jin ^a   Choi, Je Min ^a   Yang, Jung Jin ^b   Lee, Sang Kyou ^a  

^a Yonsei University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CREMOPHOR; CYCLOSPORIN A; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOMYCIN C; RAPAMYCIN; TACROLIMUS; TAUTOMYCETIN; TAUTOMYCIN;

ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 12344329599     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.6.978     Document Type: Review

References (26)

1. Huppa JB and Davis MM. T cell antigen recognition and the immunological synapse. Nat Rev Immunol 2003;3:973-83.
2. Piccirillo CA and Thornton AM. Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol 2004;25:374-80.
3. Schluns KS, Leofrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003;3:269-79.
4. Coutinho A, Poltorack A. Innate immunity: from lymphocyte mitogens to Toll-like receptors and back. Curr Opin Immunol 2003;15:599-602.
5. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-45.
6. Orme I. Adaptive immunity to mycobacteria. Curr Opin Microbiol 2004;7:58-61.
7. Jonuleit H, Adema G and Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol 2003;11:267-76.
8. Jiang S, Lechler RI. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant 2003;3:516-24.
9. Bingaman AW, Farber DL. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 2004;4:846-52.
10. Sauve D, Baratin M, Leduc C, Bonin K and Daniel C. Alloantibody production is regulated by CD4+ T cells' alloreactive pathway, rather than precursor frequency or Th1/Th2 differentiation. Am J Transplant 2004;4: 1237-45.
11. Donnenberg VS, Burekart GJ, Zeevi A, Griffith BP, Iacono A, McCurry KR, et al. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. Transplantation 2004;77:1699-706.
12. Takehisa Y, Sakiyama S, Uyama T, Sumitomo M, Tamaki M, Hino H, et al. Progressive increase of CD4(+)/CD45RC(-) lymphocytes after allograft rat lung transplantation: a marker of acute rejection. J Thorac Cardiovasc Surg 2002;124:675-83.
13. Posselt AM, Vincenti F, Bedolli M, Lantz M, Robert JP, Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation 2003;76:190-5.
14. Grazia TJ, Pietra BA, Johnson ZA, Kelly BP, Plenter RJ, Gill RG. A two-step model of acute CD4 T-cell mediated cardiac allograft rejection. J Immunol 2004; 172:7451-8.
15. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways:implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004;16:550-7.
16. Isobe M. Gene therapy for heart transplantation-associated acute rejection, ischemia/reperfusion injury and coronary arteriosclerosis. Curr Gene Ther 2004;4:145-52.
17. Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci 2004:101:14622-6.
18. Lee MK, Moore DJ, Jarrett BP, Lian MM, Deng S, Huang X, et al. Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J Immunol 2004; 172:6539-44.
19. Ohashi PS. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol 2002;2: 427-38.
20. Kahan BD. Timeline: Individuality: the barrier to optimal immunosuppression. Nat Rev lmmunol 2003;3:831-8.
21. Shim JH, Lee HK, Chang EJ, Chae WJ, Han JH, et al. Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc Natl Acad Sci 2002;99:10617-22.
22. Kabouridis PS. Biological applications of protein transduction technology. Trends Biotechnol 2003;21:498-503.
23. Joiot A, Prochiantz A. Transduction peptides: from technology to physiology. Nat Cell Biol 2004;6:189-96.
24. Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol 2002;13:52-6.
25. Choi JM, Chae WJ, Jung YK, Lee JS, Lee SK, Park CS, et al. Blockade of Airway inflammation and hyper-responsiveness in immune-sensitized mice by nasal administration of cytoplasmic domain of CTLA4 using novel protein transduction domain.; 2004; Submitted to Nature Medicine.
26. Chen CM, Breringer RR. CREating breakthroughs. Nat Biotechnol 2001;19:921-2.